A Phase 1 interventional study of dabigatran etexilate and dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-05.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran exposure (in Part II)
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
multiple doses of dabigatran (alone)
Drug: dabigatran etexilate
concomitant administration of dabigatran and ticagrelor
Drug: dabigatran etexilate · Drug: ticagrelor
staggered administration of ticagrelor and dabigatran
Drug: ticagrelor · Drug: dabigatran etexilate
multiple doses of dabigatran
medium dose dabigatran
loading dose of ticagrelor
multiple doses of ticagrelor
loading dose of ticagrelor
single dose of dabigatran
Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss).
Time frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours
Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)
Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).
Time frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours
| Milestone | Part 1 | Part 2 |
|---|---|---|
| Started | 24 | 24 |
| Completed | 23 | 21 |
| Not completed | 1 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss).
| ng*h/mL | Dabigratan Etexilate 110mg Bid Alone - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 | Dabigratan Etexilate 110mg Bid Alone - Part 2 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 |
|---|---|---|---|---|---|
| Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) | 551 ± 59.0 | 817 ± 43.3 | 689 ± 55.1 | 660 ± 39.6 | 844 ± 43.4 |
Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).
| ng/mL | Dabigratan Etexilate 110mg Bid Alone - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 | Dabigratan Etexilate 110mg Bid Alone - Part 2 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 |
|---|---|---|---|---|---|
| Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss) | 83.6 ± 69.3 | 136 ± 45.4 | 106 ± 65.1 | 97.6 ± 46.5 | 121 ± 45.2 |
Collected over 11 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigratan Etexilate 110mg Bid Alone - Part 1 | — | 0/24 (0%) | 0/24 (0%) |
| Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 | — | 0/23 (0%) | 0/23 (0%) |
| Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 | — | 0/23 (0%) | 0/23 (0%) |
| Dabigratan Etexilate 110mg Bid Alone - Part 2 | — | 0/24 (0%) | 2/24 (8.3%) |
| Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 | — | 0/21 (0%) | 0/21 (0%) |
| Event | Dabigratan Etexilate 110mg Bid Alone - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 | Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 | Dabigratan Etexilate 110mg Bid Alone - Part 2 | Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/24 | 0/23 | 0/23 | 2/24 | 0/21 |
Treated Set which includes all subjects who were documented to have received at least 1 dose of trial medication.
| Age, Continuous(years) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Mean | 28.0 ± 7.2 | 28.6 ± 7.1 | 28.3 ± 7.15 |
| Sex: Female, Male(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 24 | 24 | 48 |
The record gives a start of Nov 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor